Become a client
  • EN
  • KZ
  • RU
Back
Moderna
MRNA
Stock price
$ 117.45
Expected price
$193.42
Returns for 6 months
-32.99%
Dividend income
More
Number of shares
Commission of the bank:
0%
Brokerage commission:
0.00
Value:
Add to cart
Make an order
Add to cart
Overview
Value dynamics
$

How to assess the success of investments?

Because the investment strategy is drawn up individually, there is no unique instruction for determining profitable or unprofitable positions. It all depends on your goals and risk tolerance.

About Company Moderna

Moderna, Inc., a clinical-stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases.

As of 15 February 2019, the company had 11 programs under clinical trials and a total of 20 development candidates in six areas including preventive vaccines, cancer vaccines, intratumor immuno-oncology, localized regenerative therapies, systemic secreted therapies and systemic intracellular therapies.

The company has strategic alliances with AstraZeneca, Merck & Co, Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency and Bill & Melinda Gates Foundation and has research collaborations with Harvard University. Moderna, Inc. also cooperates with Lonza Ltd. to produce mRNA-1273, a COVID-19 vaccine, and with Catalent to produce a COVID-19 vaccine fill and finish candidate.

The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.

Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Why is it worth investing?
MRNA
$117.45
Moderna
Commission of the bank:
0%
Brokerage commission:
0.00
Value:
Add to cart
Make an order
Similar stocks
Similar stocks
Go to Catalogue